ARCH Venture Partners XII, LLC

ARCH Venture Partners XII acquires over 5M shares in SPTX IPO aftermath; major institutional vote of confidence at listing price

ARCH Venture Partners XII, a 10% beneficial owner of Seaport Therapeutics, executed a substantial open-market purchase of over 5 million shares on the stock's second trading day—a significant institutional commitment that coincides with the company's recent IPO. The timing is notable: the fund is buying at the listing price level after having already participated in the private placement rounds that likely seeded its beneficial ownership stake. This isn't insider knowledge driving the trade, but rather portfolio capital allocation—ARCH is doubling down on its conviction in the biotech therapeutics opportunity the company represents. The purchase reflects institutional confidence that the newly public shares offer fair value at current levels, which could signal that the market's initial pricing is reasonable from the fund's perspective.

VC-backed insider ARCH Venture Partners XII bought 1,915,700 shares ($5.0M) at $2.61; 5 of 5 prior NMRA buys well-timed at 90d; cluster buy.

ARCH Venture Partners XII, a 10% owner, purchased 1,915,700 shares (1.92M shares) for $5.0M on 2025-10-27, raising holdings by 46.4% to 6,046,907 shares (6.05M shares). This is notable in context of the insider's trading history at NMRA: all 5 prior purchases (November 2023) were well-timed, with 90-day returns ranging from +48.5% to +61.2%. The insider's cross-ticker track record shows a 100.00% 90-day win rate across 20 prior buys with an average 90d return of +41.6%. Additionally, 2 other insiders bought within the past 14 days, forming a cluster-buy pattern. However, fundamentals remain challenged: the company reported net income of $-52,731,000.00 ($-52.7M) and remains unprofitable. Current price of $2.50 sits 81.7% below the 52-week high of $13.64, though the stock has recovered +42.0% over the past 30 days.

Major VC fund ARCH Venture Partners XII acquired 3.03M shares of PRME for $10.0M at $3.30; now holds 6.23M (94.7% increase). Stock +31.6% in 30d, but -28.0% from 52w high.

ARCH Venture Partners XII, a 10% owner, purchased 3,030,300 shares at $3.30 on 2025-08-01 for $9,999,990.00, substantially increasing its stake to 6,230,300 shares post-transaction (94.7% increase from 3,200,000 pre-transaction shares). The insider's cross-ticker track record shows strong historical execution: 20 prior buys with an average 90-day return of +42.1% and a 100% win rate, and its sole prior PRME purchase on 2024-02-15 delivered an 8.2% 90-day return. However, PRME's fundamentals present a material headwind: the company generated only $1,454,000 in latest-quarter revenue against a net loss of $51,890,000, while the market cap stands at $530,429,594. The recent price momentum (+31.6% in 30 days) offers context, but against a 52-week high-to-current drawdown of -28.0% and sustained unprofitability, this large accumulation by a seasoned investor may reflect conviction—or a bet on an inflection in a pre-revenue or early-stage clinical program. A cluster of 3 other insiders buying within 14 days adds weight to the signal, though the company's capital burn rate and minimal revenue warrant close scrutiny on cash runway and path to profitability.

ARCH Venture Partners XII acquired 2,222,222 shares for $39,999,996.00 at $18.00; cluster buy signal with 2 other insiders in 14 days.

ARCH Venture Partners XII, a 10% owner, executed 2 separate purchases totaling 2,222,222 shares for $39,999,996.00 at $18.00 on 2025-02-03, expanding holdings from 6.09M to 8.31M shares (+36.5%). This transaction arrives just 2 trading days post-IPO, when price discovery is ongoing; the current price of $27.80 exceeds the transaction price by 54%. A cluster pattern is present—2 other insiders also bought within the past 14 days—indicating broad insider appetite at post-listing valuations. The derivative-conversion flag indicates this filing reflects a conversion event (Table II activity not yet populated); the reported Table I shares represent only the equity leg, not the insider's total derivative-adjusted position. The scale of the acquisition ($40.0M) and the participation of multiple insiders within a narrow window suggest confidence in post-IPO fundamentals, though in a very-early-stage listing environment, sustained price discovery remains ahead.